NEDD8 and hematopoietic and lymphoid cell neoplasm: We previously reported the inhibitory effect of TAS4464 on the neddylation pathway in several hematopoietic cancers [27, 31], and in this study, a similar drug functionality of TAS4464 was shown in AML cell lines by confirming the decrease in NEDD8 conjugation by Ubc12 or cullin1 (Fig. 3A).